Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05856448 · ClinicalTrials.gov registry record · Phase 2

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

A Phase 2 study of Systemic Lupus Erythematosus, sponsored by Galapagos.

Active
Registry status
Phase 2
Development phase
186
Enrollment target
20
Study locations

NCT05856448 is a Phase 2 study of Systemic Lupus Erythematosus that is active but no longer recruiting, run by Galapagos. The registered enrollment target is 186 participants, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05856448, a Phase 2 study of Systemic Lupus Erythematosus, is active but no longer recruiting, sponsored by Galapagos.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
186 participants
Enrollment target
20
Study locations

Study Summary

A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily for 48 weeks in approximately 180 adult participants with active Systemic Lupus Erythematosus (SLE).

Conditions Studied

Systemic Lupus Erythematosus

Interventions

  • DRUG Placebo
  • DRUG GLPG3667

Study Locations (20)

Florida

  • Arthritis & Rheumatic Disease Specialties - Aventura
  • Omega Research DeBary - DeBary
  • Alloy Clinical Research, LLC - Kissimmee
  • San Marcus Research Clinic - Miami
  • Advanced Pharma - Miami - Miami
  • Professional Research Center - Miami
  • Integral Rheumatology & Immunology Specialists - Plantation
  • Alliance Clinical Research of Tampa - Tampa

California

  • University of California San Diego - La Jolla
  • Desert Medical Advances - Rancho Mirage
  • Millennium Clinical Trials - Simi Valley
  • Inland Rheumatology Clinical Trials - Upland
  • Upland Rheumatology Center - Upland

Tennessee

  • New Phase Research & Development - Knoxville
  • Office of Ramesh C. Gupta MD / Shelby Research LLC - Tennessee - Memphis

Arizona

  • University of Arizona College of Medicine - Tucson - Tucson

New Mexico

  • Albuquerque Clinical Trials - Albuquerque

North Carolina

  • DJL Clinical Research - Charlotte

Oklahoma

  • Lynn Institute of Tulsa - Tulsa

Texas

  • Care and Cure Clinic - Houston

Trial Details

FieldValue
Enrollment Target 186 participants
Start Date 2023-06-28
Est. Completion 2026-03
Phase Phase 2

Sponsor

Galapagos

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05856448

The ClinicalTrials.gov registry entry for NCT05856448 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (51% lower). The listed sponsor is Galapagos, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05856448 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Tennessee.

Frequently Asked Questions

What is clinical trial NCT05856448 about?

NCT05856448 is a clinical study titled "A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus". A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily for 48 weeks in approximately 180 adult participants with active Systemic Lupus Erythematosus (SLE).

What is the current status of trial NCT05856448?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2023-06-28. Estimated completion is 2026-03.

What conditions does trial NCT05856448 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus.

What interventions are being tested in trial NCT05856448?

The interventions under investigation include: Placebo (DRUG), GLPG3667 (DRUG).

Who is sponsoring clinical trial NCT05856448?

This trial is sponsored by Galapagos, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05856448 being conducted?

This trial has 20 study locations across Arizona, California, Florida, New Mexico, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Systemic Lupus Erythematosus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Systemic Lupus Erythematosus

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.